Triumph and Togetherness: RAWF Takes on the United Airlines NYC Half Marathon
In the bustling streets of New York City, amidst the vibrant energy of the United ... Read more
Scaling New Heights: Conquering Mount Kilimanjaro with AVP-D and Thriving Beyond Rare Disease
Hiking Kilimanjaro has been a dream of mine for many years and on Sunday 25th ... Read more
Welcoming a New Addition to Our Team!
At Raymond A. Wood Foundation, we are thrilled to introduce Meghan Wood, our new Major ... Read more
2023 with RAWF: A Year in Review
2023 has been a remarkable year for the Raymond A. Wood Foundation, one filled with ... Read more
Recap: Pituitary Brain Tumor Family Conference 2023 – Advocacy, Connection, and Growth
Overview In the heart of Philadelphia, the Raymond A. Wood Foundation hosted the 5th Annual ... Read more
Raymond A. Wood Foundation Reveals Caregiver Burden in Pioneering Craniopharyngioma Study
The Raymond A. Wood Foundation recently published its first research study entitled “Caregiver burden and ... Read more
RAWF Executive Director at the IBTA World Summit in Vienna, Austria
Brain tumor patient advocates, clinicians and researchers convened in Vienna, Austria last month at the ... Read more
Development of Patient Registry Well Underway
The Raymond A. Wood Foundation hosted our first International Hypothalamic-Pituitary Brain Tumor Patient Registry advisory ... Read more
Working to Develop a Sodium Meter for DI Patients
The Raymond A. Wood Foundation (RAWF) entered an agreement with Giner Labs, a world-renowned center ... Read more
Raymond A. Wood Foundation Joins the Children’s Brain Tumor Network Executive Council
The Children’s Brain Tumor Network (CBTN) is dedicated to driving innovative discovery, pioneering new treatments and accelerating open science to improve health for all children and young adults diagnosed with a brain tumor. The CBTN is the largest pediatric brain tumor biorepository and is made up of over 40 partner foundations. This month, Raymond A. Wood Foundation (RAWF) joined those partner organizations and has pledged $50,000 in support of the growth of CBTN’s craniopharyngioma biobank to accelerate research on tumor treatment and post-treatment management.
